Increased/VBN
natural/JJ
killer/NN
cell/NN
activity/NN
correlates/VBZ
with/IN
low/JJ
or/CC
negative/JJ
expression/NN
of/IN
the/DT
HER-2/neu/NN
oncogene/NN
in/IN
patients/NNS
with/IN
breast/NN
cancer/NN
./.

BACKGROUND/NN
./.
=====
Increased/VBN
expression/NN
of/IN
the/DT
HER-2/neu/NN
oncogene/NN
in/IN
breast/NN
cancer/NN
correlates/VBZ
with/IN
decreased/VBN
estrogen/NN
receptor/NN
concentration/NN
and/CC
seems/VBZ
to/TO
be/VB
an/DT
important/JJ
prognostic/JJ
factor/NN
./.
=====
The/DT
authors/NNS
investigated/VBD
whether/IN
there/EX
is/VBZ
a/DT
correlation/NN
between/IN
HER-2/neu/NN
expression/NN
and/CC
immunologic/JJ
parameters/NNS
representing/VBG
tumor/NN
defense/NN
in/IN
patients/NNS
with/IN
breast/NN
cancer/NN
./.
=====
METHOD/NN
./.
=====
A/DT
Western/JJ|NN
blot/NN
analysis/NN
was/VBD
used/VBN
to/TO
investigate/VB
HER-2/neu/NN
expression/NN
,/,
whereas/IN
a/DT
chromium-release/NN
assay/NN
using/VBG
the/DT
K562/NN
cell/NN
line/NN
as/IN
target/NN
was/VBD
used/VBN
to/TO
measure/VB
natural/JJ
killer/NN
(/(
NK/NN
)/)
cell/NN
activity/NN
./.
=====
RESULTS/NNS
./.
=====
In/IN
patients/NNS
with/IN
breast/NN
cancer/NN
,/,
NK/NN
cell/NN
activity/NN
was/VBD
significantly/RB
higher/JJR
compared/VBN
with/IN
patients/NNS
with/IN
benign/JJ
tumors/NNS
(/(
P/NN
=/JJ
0.006/CD
)/)
or/CC
healthy/JJ
control/NN
subjects/NNS
(/(
P/NN
=/JJ
0.002/CD
)/)
./.
=====
Moreover/RB
,/,
23.3/CD
%/NN
of/IN
patients/NNS
with/IN
breast/NN
cancer/NN
showed/VBD
an/DT
overexpression/NN
of/IN
HER-2/neu/NN
protein/NN
./.
=====
Within/IN
this/DT
group/NN
of/IN
patients/NNS
,/,
NK/NN
cell/NN
activity/NN
was/VBD
significantly/RB
lower/JJR
(/(
45.6/CD
+/-/CC
16.1/CD
%/NN
)/)
compared/VBN
with/IN
the/DT
group/NN
with/IN
no/DT
HER-2/neu/NN
overexpression/NN
(/(
57.3/CD
+/-/CC
11.0/CD
%/NN
)/)
./.
=====
NK/NN
cell/NN
activity/NN
did/VBD
not/RB
increase/VB
in/IN
patients/NNS
with/IN
HER-2/neu/NN
overexpression/NN
./.
=====
Thus/RB
,/,
there/EX
was/VBD
a/DT
statistically/RB
significant/JJ
correlation/NN
of/IN
cytolytic/JJ
effector/NN
cell/NN
function/NN
with/IN
HER-2/neu/NN
expression/NN
of/IN
the/DT
tumor/NN
(/(
P/NN
=/JJ
0.003/CD
)/)
,/,
and/CC
HER-2/neu/NN
overexpression/NN
correlated/VBD
with/IN
a/DT
negative/JJ
estrogen/NN
receptor/NN
status/NN
(/(
P/NN
=/JJ
0.005/CD
)/)
./.
=====
CONCLUSION/NN
./.
=====
These/DT
data/NNS
add/VBP
further/JJ
evidence/NN
to/TO
previous/JJ
observations/NNS
from/IN
the/DT
authors/NNS
'/POS
laboratory/NN
that/IN
certain/JJ
tumor/NN
characteristics/NNS
may/MD
be/VB
associated/VBN
with/IN
reactions/NNS
of/IN
the/DT
host/NN
with/IN
breast/NN
cancer/NN
./.